InsidersTradesSigma
Total declarations
Companies
▲ Purchases (4 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
4
Disclosed sells
0
T+90 hit rate
100%
T+90 mean return
+11.2%
Across 4 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the full record of transactions filed by MERRIFIELD C ANN, Director. Insider active across 2 companies, notably Lyra Therapeutics, Inc.. Aggregated, 8 reports have been published. Breakdown: 4 buys · 0 sell. Total volume traded: €88k. History available since 17 June 2021. The latest transaction was filed on 10 June 2022 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations8 total
4,000 shares@ US$5.051.53% mcap21.6% of flowCommon StockSEC:0000899243-22-022154:0
Ideal exit: 7 Mar 2023 (T+270)
3,500 shares@ US$4.8131.31% mcap18.5% of flowCommon StockSEC:0000899243-22-018435:0
Ideal exit: 7 Feb 2023 (T+270)
19,000 shares@ US$8.5050.0% of flowCommon StockSEC:0001209191-21-065720
19,000 shares@ US$8.5050.0% of flowCommon StockSEC:0001209191-21-065720:0
4,500 shares0Common StockSEC:0001209191-21-043555
4,500 shares0Common StockSEC:0001209191-21-043555:0
3,500 shares@ US$8.96992.12% mcap30.0% of flowCommon StockSEC:0000899243-21-025288:0
Ideal exit: 14 Mar 2022 (T+270)
3,500 shares@ US$8.969930.0% of flowCommon StockSEC:0000899243-21-025288
Ideal exit: 14 Mar 2022 (T+270)
8 of 8 declarations
About MERRIFIELD C ANN
C. Ann Merrifield is a Director at Lyra Therapeutics, Inc. and Flexion Therapeutics Inc. She plays an important role in the governance and strategy of these companies. Her expertise in biotechnology contributes to guiding strategic decisions and supporting innovation.
